Double Dose Platelet
Double Dose Platelet - Related Videos
12:40
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
0 Views •
Cited by 4 •
2012
This article describes the process used by Örebro University Hospital to produce double dose buffy coat platelet concentrates prepared from whole blood donations and treated with the INTERCEPT Blood System for pathogen inactivation. The in vitro quality of the final platelet units are evaluated over 7 days of storage.
06:04
LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism
0 Views •
Cited by 7 •
2016
Here we show isolated human platelets can be used as an accessible ex vivo model to study metabolic adaptations in response to the complex I inhibitor rotenone. This approach employs isotopic tracing and relative quantification by liquid chromatography-mass spectrometry and can be applied to a variety of study designs.
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
0 Views •
Cited by 5 •
2017
We describe a straightforward method for the isolation of washed platelets from human blood followed by agonist-induced platelet aggregation measurements by turbidimetry. As an example we apply this method for studying the aggregation response of human platelets to collagen after a pre-incubation with the Pannexin1 channel inhibitor Brilliant Blue FCF.
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
0 Views •
Cited by 13 •
2017
This paper describes an experimental model of hemostasis that simultaneously measures platelet function and coagulation. Platelet and fibrin fluorescence is measured in real-time, and platelet adhesion rate, coagulation rate, and onset of coagulation are determined. The model is used to determine platelet procoagulant properties under flow in concentrates for transfusion.
03:58
Purification and Activation of Platelets from Murine Whole Blood
0 Views •
2025
In this video, we describe a protocol for purifying platelets from murine whole blood and their subsequent activation with the platelet agonist thrombin. When analyzed with flow cytometry, the purified resting platelets are characterized based on the expression of their cell-surface marker CD41, whereas purified activated platelets co-express both the surface markers CD41 and CD62P.
FAQs
An automated blood separator centrifuges anticoagulated blood to separate its components by physical characteristics. The system selectively retains platelets while returning most red cells and plasma to the donor. This controlled separation allows collection of a larger platelet yield during one procedure, rather than combining platelet components from multiple whole-blood donations.
Collection settings can be tailored to the donor’s size and platelet count. These factors help guide how the automated separator performs the collection while supporting an appropriate platelet yield. Adjusting the process is important because donors do not have identical circulating blood volumes or platelet concentrations, making individualized collection parameters relevant to component quality and donor management.
A double-dose component is usually collected from one donor, whereas pooled platelets may combine components from multiple whole-blood donations. The single-donor approach can reduce donor exposure for the recipient and produce a more consistent platelet yield. It also changes inventory handling by providing a higher-dose component without assembling an equivalent amount from several separate collections.
This component may support patients with thrombocytopenia, a reduced platelet count, or patients experiencing active bleeding. Its higher platelet yield can help align the transfusion component with situations requiring substantial platelet support. Clinical use still depends on the patient’s condition and the transfusion strategy, so the component is relevant to both preventive and urgent medical management contexts.
The process begins with donor screening, followed by collection through an automated blood separator using anticoagulated blood. The machine centrifuges the blood, retains platelets, and returns most red cells and plasma. Collection settings may be adjusted for donor size and platelet count, while quality control helps verify that the resulting component meets the intended platelet-yield requirements.
A higher-yield component can simplify inventory management by supplying approximately two standard adult therapeutic doses in one unit. Because it generally comes from one donor, the approach may also reduce recipient donor exposure compared with assembling the same support from multiple donations. These features can be useful when platelet demand is high and efficient component availability matters.